2 Pharma Stocks Soaring on Regulatory Wins

KMPH received two price-target hikes after an FDA nod

Managing Editor
Feb 26, 2018 at 10:29 AM
facebook twitter linkedin


Several pharmaceutical stocks have been making outsized moves in recent weeks. Today, KemPharm Inc (NASDAQ:KMPH) and Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stocks are in the spotlight, thanks to encouraging regulatory news. At last check, KMPH was trading 3.1% higher at $6.18, after jumping on Friday, and ACHN stock was up 10.5% to trade at $3.27.

Analysts React to KMPH FDA Approval

KemPharm late Friday said the Food and Drug Administration (FDA) approved its opioid painkiller Apadaz for short-term acute pain management. As such, the shares touched an almost two-year high of $7.15 during Friday's trading.

In response, the drug concern received two price-target raises -- to $11 from $7 at Canaccord Genuity, and to $12 from $9 at RBC. However, Cowen and Company cut its price target to $15 from $55.

Covering analysts were optimistic toward the drug stock ahead of the Apadaz news, with all three carrying "strong buy" recommendations. Looking broader, KMPH has had a respectable year on the charts, picking up over 120% in the past six months alone.

ACHN Higher on Positive EMA Panel News

Shares of ACHN are soaring today, after a European Medicines Agency (EMA) panel issued a positive orphan status view for the company's C3G kidney drug, ACH-4471. The penny stock hit a more than three-year low of $2.58 on Feb. 1, but is now pacing for its highest finish since late November, and a second close atop its 80-day moving average -- a feat not accomplished since October.

Short interest on the drugmaker picked up more than 17% over the past two reporting periods, and now represents 6.1% of the stock's total available float. At Achillion Pharma stock's average daily trading volume, it would take about four days for the shorts to cover their bearish bets -- which could translate into a short-covering tailwind.

 

Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 

 


 


 
Special Offers from Schaeffer's Trading Partners